Imperial College Healthcare NHS Trust (ICHT)

Imperial College Healthcare NHS Trust was created in October 2007 by merging St Mary’s NHS Trust and Hammersmith Hospitals NHS Trust and integrating with the faculty of medicine at Imperial College London. In 2009 the Trust came together with the College to establish one of the UK’s first academic health science centres (AHSCs).

Imperial College Healthcare NHS Trust comprises Charing Cross, Hammersmith, Queen Charlotte’s & Chelsea, St Mary’s and Western Eye hospitals.

With more than one million patient contacts each year, it is one of the largest acute Trusts in the country and has some of the lowest mortality rates according to the 2011 Dr Foster Guide. It has an annual turnover of around £900 million and is one of eleven National Institute for Health Research (NIHR) Biomedical Research Centres.


Imperial College Healthcare’s clinical services are organised into four clinical divisions which each contain a range of specialties.

The clinical divisions are:

  • Investigative sciences and clinical support
  • Medicine
  • Surgery, cancer and cardiovascular
  • Women’s and children’s

In June 2012 the Trust joined a group of eleven North West London healthcare providers who, together with Imperial College London, formed a new partnership to improve the health and care of the local population. Imperial College Health Partners aims to improve the health and care of the population of 1.9 million people living in North West London.

The partnership, which is a limited company, brings together healthcare providers in North West London, including acute and specialist hospitals, mental health and community care services, in partnership with Imperial College London to drive practical improvements to the quality of healthcare delivery. By coordinating the adoption of innovation, the partnership aims to bring benefits to the health of the local population and, through the dissemination of best practice, extend these more widely within the UK and beyond.

Imperial College Health Partners complements the existing Academic Health Science Centre between Imperial College London and Imperial College Healthcare NHS Trust, which focuses on the early translation of research into patient care.

Research Excellence
As an Academic Health Science Centre (AHSC), translational research and education is vital. Imperial College London has a campus on all its main sites and is increasingly integrated with all their clinical specialties. The clinical sciences centre of the Medical Research Council is also based at Hammersmith Hospital, providing a strong foundation for clinical and scientific research. The Trust is also one of eleven NIHR Biomedical Research Centres. This designation is given to the most outstanding NHS and university research partnerships in the country; leaders in scientific translation and early adopters of new insights in technologies, techniques and treatments for improving health.

Recent highlights for the Trust’s research programmes include the following examples:

  • A St Mary’s Hospital-based study has helped young patients with severe asthma to a better quality of life through a novel ‘air cleaning’ machine;
  • In a world-first, surgeons at St Mary’s Hospital have used new robotic technology to perform surgery on a patient with a complex aortic aneurysm;
  • The Trust has published a UK-first research study which could potentially give people with Parkinson’s disease a new lease of life.

A new research facility designed to translate scientific discoveries into new ways of preventing, diagnosing and treating diseases opened at Hammersmith Hospital in May 2012. The £73 million Imperial Centre for Translational and Experimental Medicine (ICTEM) is a flagship facility for the Imperial AHSC combining laboratory space for up to 450 scientists with a dedicated facility for evaluating and developing new medical treatments through clinical trials with patients.

In partnership with Imperial College, our Biomedical Research Centre was awarded £112 million from NIHR and funding began in April 2012 for five years. This will be used to facilitate the continued development of cutting-edge translational research and healthcare innovations. The funding will be used to translate research into better patient care in areas including cancer, diabetes, heart disease, neuroscience, renal medicine and transplantation, paediatrics and women’s health.

Imperial AHSC was also successful in renewing core funding from the NIHR for the Wellcome Trust-McMichael Clinical Research Facility (£10.9 million to support studies into treatments for conditions like cancer, diabetes, stroke and obesity) and for the NIHR Patient Safety Translational Research Centre (£7.2 million to advance and refine new ways of improving safety in hospitals, GP surgeries and in the community).

In 2011/12 Imperial AHSC recruited over 9,000 patients into NIHR Clinical Research Network portfolio studies and more than 23,000 patients overall into clinical research, which resulted in £4.1m of support income from the London (North West) Comprehensive Local Research Network.

Performance Facts
The Hospital Standardised Mortality Rate (HSMR) data demonstrates that the Trust has one of the lowest mortality rates in the country. The national average is calculated at 100 per cent and the Trust is substantially below this at 70 per cent.

In April 2011, the Trust published its first patient and public involvement (PPI) strategy. The broad aim of the strategy is to ensure the Trust is a responsive organisation that seeks and acts on feedback.

This year’s National Inpatient Survey results demonstrated that the Trust is moving up four places in the London-wide ranking, with the third best score in London. It is the top acute Trust in North West London for patient experience.

Chief Executive: Ian Dalton CBE

© 2018 — The Shelford Group

Keep up to date

Follow The Shelford Group on Twitter and our RSS Feed.

If you would like more information about the Shelford Group or to get in touch, please click here